| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
29.04.2025 16:39:14
|
Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
ALK (ALKB.DC / OMX: ALK B) will publish its results for the first quarter of 2025 in the morning on Tuesday, 6 May 2025.
Later on the same day, the company will host a presentation for investors and analysts at 11:00 a.m. CEST, where ALK’s management will comment on the results and outlook and be available for questions.
ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.
Live audio webcast
The meeting will be audio webcasted live and be available for replay on ALK’s website.
Conference call
If you wish to participate via telephone, please register for the conference call by using this link: Registration - ALK Q1 2025 - telephone conference and follow the instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com and/or check your spam filter. We advise you to register on the day before the call at the latest.
Presentation
The presentation will be available on ALK's website shortly before the meeting starts.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
Nachrichten zu Alk-Abello A-S Bearer and-or registered Shs -B-
|
02.05.25 |
ALK enters into neffy® co-promotion agreement in the USA (GlobeNewswire) | |
|
23.04.25 |
ITULAZAX® tree pollen tablet approved for treatment of children in Europe (GlobeNewswire) | |
|
21.04.25 |
Erste Schätzungen: Alk-Abello A-S Bearer and-or registered B zieht Bilanz zum abgelaufenen Quartal (finanzen.net) | |
|
27.02.25 |
FDA approves ODACTRA® for the treatment of house dust mite allergy in young children (GlobeNewswire) | |
|
18.02.25 |
Ausblick: Alk-Abello A-S Bearer and-or registered B stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net) | |
|
04.02.25 |
Erste Schätzungen: Alk-Abello A-S Bearer and-or registered B zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
|
18.12.24 |
Positive results advance peanut tablet to phase II development (GlobeNewswire) | |
|
12.12.24 |
ACARIZAX® approved in Europe for treatment of young children (GlobeNewswire) |